Great to be listed in Labiotech.eu’s 18 UK biotech startups you’ll want on your radar in 2026!
At Ignota Labs we identify and turn around failing drugs with hidden potential, bringing new life to abandoned projects and new hope to patients.
Many drugs fail not because they are ineffective, but due to a poor understanding of their interaction with human biology. In preclinical and clinical studies, safety assessments typically reveal what went wrong—such as liver damage or heart issues—but critically not why. This gap forces the pharmaceutical industry to abandon promising therapies as sunk cost, discarding years of research and investment.
Our AI platform combines advanced machine learning models with a multimodal data approach to enable a deep understanding of toxicity mechanisms, and offers actionable insights to facilitate drug turnaround. This includes solving causes of toxicity, optimising dosing regimens, and clinical repositioning. Our approach uses AI to unlock the value in failed drugs, and returns them to the clinic as soon as possible.i
Read more:
18 UK biotech companies you should know about can be read in full at Labiotech.eu
Published: 3 March 2026 by Labiotech.eu.
